Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment

Urology

Volumn 65, Issue 6, 2005, Pages 1238-1243

  Miyata, Yasuyoshi ^a   Kanda, Shigeru ^b   Sakai, Hideki ^b   Hakariya, Tomoaki ^b   Kanetake, Hiroshi ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; APOPTOSIS INDUCING FACTOR; DNA NUCLEOTIDYLEXOTRANSFERASE; GONADORELIN AGONIST; PROTEIN BAX; PROTEIN BCL 2;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 20444435607     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2005.01.028     Document Type: Article

References (30)

1. E.C. Jones Resection margin status in radical prostatectomy specimens relationship to type of operation, tumor size, tumor grade and local tumor extension J Urol 144 1990 89 93
2. A.W. Partin, S. Piantadosi, M.G. Sanda Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy Urology 45 1995 831 838
3. R.B. Watson, M.S. Soloway Neoadjuvant hormonal treatment before radical prostatectomy Semin Urol Oncol 14 1996 48 56
4. H.H.K. Lee, P. Warde, M.A.S. Jewett Neoadjuvant hormonal therapy in carcinoma of the prostate BJU Int 83 1999 438 448
5. J.A. Weider, M.S. Soloway Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy J Urol 160 1998 299 315
6. W.W. Bonney, A.R. Schned, D.S. Timberlake Neoadjuvant androgen ablation for localized prostatic cancer pathology methods, surgical endpoints and meta-analysis of randomized trials J Urol 160 1998 1754 1760
7. F. Labrie, L. Cusan, J.L. Gomez Down-staging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy Cancer Surv 23 1995 149 156
8. M.S. Soloway, R. Sharifi, Z. Wajsman Lupron Depot Neoadjuvant Prostate Cancer Study Group Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockage in clinical stage B2 (T2bNxM0) prostate cancer J Urol 154 1995 424 428
9. S.L. Goldenberg, L.H. Klotz, J. Srigley Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer J Urol 156 1996 873 877
10. L.H. Klotz, S.L. Goldenberg, M. Jewett Canadian Urologic Oncology Group CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy 36-month post treatment PSA result Urology 53 1999 757 763
11. M.J. Scolieri, A. Altman, M.I. Resnick Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 164 2000 1465 1472
12. M.E. Gleave, S.L. Goldenberg, J.L. Chin Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy biological and pathological effects J Urol 166 2001 500 507
13. M.E. Gleave, S.L. Goldenberg, E.C. Jones Biochemical and pathological effect of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer J Urol 155 1996 213 219
14. T.H. Van der Kwast, B. Tetu, B. Candas Prolonged neoadjuvant combined androgen blockage leads to a further reduction of prostatic tumor volume three versus six months of endocrine therapy Urology 53 1999 523 529
15. J.C. Reed Bcl-2 and the regulation of programmed cell death J Cell Biol 124 1994 1 6
16. N.M. Kernohan, L.S. Cox Regulation of apoptosis by Bcl-2 and its related proteins immunohistochemical challenges and therapeutic implications J Pathol 179 1996 1 3
17. P. Stattin, P. Westin, J.E. Damber Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer Br J Cancer 77 1998 670 675
18. H. Matsushima, T. Goto, Y. Hosaka Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation Cancer 85 1999 1822 1827
19. B. Szende, I. Romics, K. Minik Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma Prostate 49 2001 93 100
20. A.I. So, A. Hurtado-Coll, M.E. Gleave Androgens and prostate cancer World J Urol 21 2003 325 337
21. B. Szende, T. Lubben, I.I. Romics Apoptosis in untreated and hormone treated prostate cancer of various histological types Pathol Oncol Res 2 1996 239 241
22. M. Colecchia, B. Frigo, C. Del Boca Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy J Clin Pathol 50 1997 384 388
23. R.F. Paterson, M.E. Gleave, E.C. Jones Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy Mol Urol 3 1999 277 286
24. S. Bencini, M. Migaldi, G. Castagnetti Apoptosis in prostate carcinoma before and after therapy with LH-RH analog Ann NY Acad Sci 1010 2003 789 792
25. Y. Miyata, S. Koga, S. Kanda Expression of cyclooxygenase-2 in renal cell carcinoma correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival Clin Cancer Res 9 2003 1741 1749
26. Y. Miyata, H. Sakai, H. Kanda Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues correlation with histopathological effects and biochemical recurrence Urology 63 2004 1184 1190
27. T.J. McDonnell, P. Troncoso, S.M. Brisbay Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944
28. J. Pinski, A.V. Schally, T. Yano Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals Prostate 23 1993 165 178
29. R. Montironi, C. Magi-Galluzzi, S. Marina Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology J Cell Biochem 19 1994 238 245
30. M. Tsujii, Y. Murakami, H. Kanayama Immunohistochemical analysis of Ki-67 antigen and bcl-2 protein expression in prostate cancer effect of neoadjuvant hormonal therapy Br J Urol 81 1998 116 121